Dominick J. Angiolillo

University of Florida — United States

Medicine · Health Sciences

109h-index52.9kcitations1.1kworks7.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Antiplatelet Therapy and Cardiovascular Diseases(837), Coronary Interventions and Diagnostics(350), Acute Myocardial Infarction Research(332), Atrial Fibrillation Management and Outcomes(224), Venous Thromboembolism Diagnosis and Management(206)

Publications1.1k total

Safety and Efficacy of Colchicine across the Spectrum of Coronary Artery Disease: A Systematic Review and Meta-Analysis of 20 Randomized Trials.
PubMed·2026
Real-World Adoption of the 2023 European Society of Cardiology Guidelines Regarding Antiplatelet Strategies in Acute Coronary Syndromes: Insights from the European READAPT-2 survey
SSRN Electronic Journal·2026Open Access
Prasugrel or ticagrelor monotherapy vs dual antiplatelet treatment after percutaneous coronary intervention in acute coronary syndromes: a landmark analysis from the NEO-MINDSET trial
European Heart Journal·2025· 1 citedOpen Access
Overview of Antiplatelet Therapy for Acute Coronary Syndrome
Elsevier eBooks·2025
Contributors
Elsevier eBooks·2025
Reply
JACC: Cardiovascular Interventions·2025
The role of oxidized phospholipids on thrombotic risk
Journal of Thrombosis and Thrombolysis·2025Open Access
Potent P2Y12 Inhibitor Monotherapy vs DAPT After PCI in Patients With and Without STEMI
Journal of the American College of Cardiology·2025· 2 cited
Use of Cangrelor for Patients Undergoing Coronary Artery Bypass Grafting
JACC Advances·2025Open Access
Aspirin or P2Y12 inhibitor monotherapy in atherosclerotic cardiovascular disease?
European Heart Journal·2025· 3 cited
Long-term safety of oral antiplatelet strategies for patients with acute coronary syndrome undergoing percutaneous coronary intervention
Expert Opinion on Drug Safety·2025
Abstract 4364354: <i>CYP2C19-</i> Guided Therapy Antiplatelet Therapy Influences Outcomes After Percutaneous Coronary Intervention in Black Patients
Circulation·2025
Dual antithrombotic therapy in venous thromboembolism: A propensity-matched analysis of safety and efficacy by anticoagulant type. insights from the riete registry.
Blood·2025
Rationale and design of REAC-TAVI 2: Single antiplatelet treatment with ticagrelor vs aspirin after transcatheter aortic valve implantation
American Heart Journal·2025
Optimizing selection of P2Y <sub>12</sub> inhibiting therapy: clopidogrel, prasugrel or ticagrelor
Expert Opinion on Pharmacotherapy·2025
Impact of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition on Platelet Reactivity in Patients with Atherosclerotic Cardiovascular Disease: A Pooled Analysis of Two Randomized Double-blind Placebo-controlled Studies
Thrombosis and Haemostasis·2025
Validation of the Mayo Clinic Percutaneous Coronary Intervention Risk Prediction Score in Patients With Acute Coronary Syndrome
Journal of the American Heart Association·2025Open Access
A-129 ANALYTICAL VALIDATION OF THE NEXT-GENERATION T-TAS wS SYSTEM
Clinical Chemistry·2025Open Access
TCT-996 One-versus three-month DAPT in High Bleeding Risk Patients With or Without Baseline Anemia Undergoing PCI
Journal of the American College of Cardiology·2025
TCT-69 Optimal P2Y12 inhibitor strategy after acute coronary syndrome: a network meta-analysis of randomised controlled trials
Journal of the American College of Cardiology·2025
page 1 of 54Next →

Frequent Co-authors

Deepak L. Bhatt(12), Matthew J. Price(12), Marco Valgimigli(10), Dirk Sibbing(9), C. Michael Gibson(9), Fernándo Alfonso(9), Robert F. Storey(8), Roxana Mehran(8), Theodore A. Bass(8), Manel Sabaté(8), Dietmar Trenk(7), Javier Escaned(7), Antonio Fernández‐Ortíz(7), Esther Bernardo(7), Carlos Macaya(7), Marco A. Costa(7), Davide Capodanno(7), Adnan Kastrati(6), Paul A. Gurbel(6), Gregg W. Stone(6)